go-v.orgdoi

Efficacy and Safety of Thalidomide for Chemotherapy-induced Nausea and Vomiting

Nan Wang, Peng Xu, Yu Liu, Peng Zhao, Jian Ruan, Yi Zheng, Junpei Jin, Shuqian Wang, Jiaxi Yao, Dong Xiang, Dai Zhang, Na Li, Huafeng Kang, Zhijun Dai · Journal of Cancer · 2020

  • DOI 10.7150/jca.45678
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2020

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2020

Abstract

Purpose: A substantial number of cancer patients discontinue chemotherapy due to severe chemotherapy-induced nausea and vomiting (CINV).This study aimed to evaluate the efficacy and safety of thalidomide (THD) in CINV.Methods: We searched different databases to identify related studies that investigated the efficacy and safety of THD in CINV.The primary outcomes were CINV in the acute (0-24 h), delayed (24-120 h), and overall (0-120 h) phases, respectively.The secondary outcomes were the safety of THD and the patients' quality of life (QOL).Results: Fourteen randomized control trials (RCTs) including 1744 patients (42% male) reported the risk ratio (RR) and 95%CI of the THD group versus control group in reducing nausea and vomiting.Meta-analysis showed that THD statistically enhanced the complete response rate of nausea and vomiting in the delayed (nausea: RR = 1.69, 95%CI: 1.47-1.94;vomiting: RR = 1.38, 95%CI: 1.26-1.51)and overall phases (nausea: RR = 1.54, 95%CI: 1.31-1.81;vomiting: RR = 1.31, 95%CI: 1.18-1.46).Furthermore, subgroup analysis based on THD dosage (100 vs 200 mg/day) demonstrated no statistical significance with respect to overlapping 95%CI.Thirty studies monitored the adverse events (AEs) of THD, all under grade 3 based on the CTCAE criteria.We compared the eight most common AEs; sedation, constipation, and drowsiness/dizziness were slightly frequent compared with controls.Conclusion: THD is an effective adjuvant and a potential alternative in reducing delayed and overall CINV.Other regimens might be added for CINV during the acute phase.

Open the resolved locator · 10.7150/jca.45678

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:53 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v11p4560.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.